Empiric proton pump inhibitor therapy after esophageal food impaction may mask eosinophilic esophagitis diagnosis at follow-up
| Autor: | Sarah Donohue, Luis D. Lomeli, Luke Hillman, Patrick Hoversten, Eric A. Gaumnitz, Aimee Teo Broman |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Adult
medicine.medical_specialty medicine.drug_class Proton-pump inhibitor Gastroenterology 03 medical and health sciences 0302 clinical medicine Internal medicine Biopsy medicine Humans Eosinophilic esophagitis Retrospective Studies medicine.diagnostic_test Esophagogastroduodenoscopy business.industry Proton Pump Inhibitors Retrospective cohort study Eosinophilic Esophagitis General Medicine Odds ratio medicine.disease Confidence interval 030220 oncology & carcinogenesis 030211 gastroenterology & hepatology Deglutition Disorders business Empiric therapy Follow-Up Studies |
| Zdroj: | Diseases of the Esophagus. 34 |
| ISSN: | 1442-2050 1120-8694 |
| Popis: | SummaryEsophageal food impaction (EFI) is often the first presentation for patients with eosinophilic esophagitis (EoE); however, there is significant heterogeneity in the management of EFI. We aimed to study the impact of EFI management, particularly post-EFI medication prescriptions on EoE diagnosis, follow-up, and recurrence in patients with endoscopic features of EoE. In our retrospective study, adults presenting between 2007 and 2017 with EFI requiring endoscopic dis-impaction with endoscopic features of EoE (furrows, rings, and/or exudates) were included. We examined the impact of demographics and EFI management on EoE diagnosis, follow-up (esophagogastroduodenoscopy [EGD] or clinic visit within 6 months), and recurrence. We identified 164 cases of EFI due to suspected EoE. Biopsy was performed in 68 patients (41.5%), and 144 patients (87.8%) were placed on proton pump inhibitor (PPI) and/or swallow corticosteroids after EFI, including 88.5% of those not biopsied. PPI use at time of biopsy was negatively associated with EoE diagnosis (odds ratio: 0.39, confidence interval: 0.17–0.85). Sixty-one (37.4%) patients were lost to follow-up at 6 months. Recurrent EFI at 1 year occurred in 3.7% of patients. Medications, most commonly PPI, are frequently prescribed after EFI when the endoscopic features of EoE are present, which may mask the diagnosis of EoE on follow-up EGD. We estimated that for every five patients biopsied on PPI, one case of EoE is masked. As recurrent EFI within 1 year is uncommon, empiric therapy should be avoided until diagnostic biopsies are obtained. Further efforts to reduce loss to follow-up after EFI are also needed. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|